UroGen Pharma Ltd.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
URGN$25.32-3.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Shareholders’ Deficit
(unaudited; in thousands, except share amounts)
| Ordinary Shares | ||||||
|---|---|---|---|---|---|---|
| Number of · Additional paid-in · Accumulated · Accumulated other comprehensive | ||||||
| Shares | Amount | capital | Deficit | income (loss) | Total | |
| Balance as of July 1, 2025 | 46,199,134 | $126 | $806,497 | $(900,005) | $6 | $(93,376) |
| Changes During the Three Months Ended September 30, 2025 | ||||||
| Exercise of options into ordinary shares | 165,829 | 1 | 301 | 302 | ||
| Share-based compensation | 3,027 | 3,027 | ||||
| Issuance of ordinary shares, net of issuance costs | 416,248 | 1 | 7,968 | 7,969 | ||
| Other comprehensive income | 17 | 17 | ||||
| Net loss | (33,347) | (33,347) | ||||
| Balance as of September 30, 2025 | 46,781,211 | $128 | $817,793 | $(933,352) | $23 | $(115,408) |
| Balance as of July 1, 2024 | 41,169,954 | $112 | $775,270 | $(745,037) | (31) | $30,314 |
| Changes During the Three Months Ended September 30, 2024 | ||||||
| Exercise of options into ordinary shares | 99,433 | — | 115 | 115 | ||
| Share-based compensation | 3,489 | 3,489 | ||||
| Issuance of ordinary shares, net of issuance costs | 921,428 | 3 | 15,000 | 15,003 | ||
| Other comprehensive income | 267 | 267 | ||||
| Net loss | (23,673) | (23,673) | ||||
| Balance as of September 30, 2024 | 42,190,815 | $115 | $793,874 | $(768,710) | $236 | $25,515 |
UroGen Pharma Ltd.
Condensed Consolidated Statements of Shareholders’** Deficit**
(unaudited; in thousands, except share amounts)
| Ordinary Shares | ||||||
|---|---|---|---|---|---|---|
| Number of · Additional paid-in · Accumulated · Accumulated other comprehensive | ||||||
| Shares | Amount | capital | Deficit | income (loss) | Total | |
| Balance as of January 1, 2025 | 42,231,746 | $115 | $797,248 | $(806,222) | $56 | $(8,803) |
| Changes During the Nine Months Ended September 30, 2025 | ||||||
| Exercise of options into ordinary shares | 552,103 | 2 | 627 | 629 | ||
| Share-based compensation | 8,829 | 8,829 | ||||
| Conversion of pre-funded warrants into ordinary shares | 3,206,271 | 9 | (6) | 3 | ||
| Issuance of ordinary shares, net of issuance costs | 791,091 | 2 | 11,095 | 11,097 | ||
| Other comprehensive loss | (33) | (33) | ||||
| Net loss | (127,130) | (127,130) | ||||
| Balance as of September 30, 2025 | 46,781,211 | $128 | $817,793 | $(933,352) | $23 | $(115,408) |
| Balance as of January 1, 2024 | 32,490,119 | $89 | $614,035 | $(679,348) | 12 | $(65,212) |
| Changes During the Nine Months Ended September 30, 2024 | ||||||
| Exercise of options into ordinary shares | 378,800 | 1 | 249 | 250 | ||
| Share-based compensation | 9,805 | 9,805 | ||||
| Issuance of pre-funded warrants, net of issuance costs | 18,641 | 18,641 | ||||
| Issuance of ordinary shares, net of issuance costs | 9,321,896 | 25 | 151,144 | 151,169 | ||
| Other comprehensive income | 224 | 224 | ||||
| Net loss | (89,362) | (89,362) | ||||
| Balance as of September 30, 2024 | 42,190,815 | $115 | $793,874 | $(768,710) | $236 | $25,515 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.